Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents as of June 30, 2025, together with $2.2 million of net proceeds raised under its at-the-market offering program from July 1, 2025 through August 1, 2025, will be sufficient to fund its operations into 2026. The foregoing estimate gives effect to Iterum’s currently planned commercial launch of ORLYNVAH in August 2025. As of August 1, 2025, Iterum had approximately 44.7 million ordinary shares outstanding.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM:
- Iterum Therapeutics Signs Manufacturing Agreement with ACS Dobfar
- Iterum Therapeutics Sets AGM Date for September 2025
- Iterum Therapeutics appoints Coyne as CCO
- Iterum Therapeutics announces publication of REASSURE trial in NEJM Evidence
- Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch